Moderna, Inc. (NASDAQ:MRNA – Get Free Report) was up 5.6% during mid-day trading on Tuesday . The stock traded as high as $187.20 and last traded at $182.56. Approximately 23,758,405 shares changed hands during trading, an increase of 101% from the average session volume of 11,791,728 shares. The stock had previously closed at $172.94.
Trending Headlines about Moderna
Here are the key news stories impacting Moderna this week:
- Positive Sentiment: Phase 3 INTerpath-001 results for intismeran autogene plus Merck’s Keytruda in high-risk melanoma previously met the trial’s endpoints. The positive outcome has become the primary catalyst behind Moderna’s roughly 510% one-year advance. Was Moderna Stock’s Cancer Vaccine Run Visible in Advance?
- Positive Sentiment: Detailed Phase 3 melanoma data will be presented at a Presidential Symposium during the European Society for Medical Oncology (ESMO) Congress on October 24. The prominent presentation slot is increasing investor confidence that the results could be clinically meaningful. Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
- Positive Sentiment: Moderna will provide three ESMO abstracts covering melanoma and updates involving the personalized therapy in pancreatic and lung cancers, broadening the potential opportunity beyond the initial indication. Moderna To Present Additional Data From Key Melanoma Trial At ESMO Congress
- Positive Sentiment: Investors are also positioning ahead of a late-October data release and Moderna’s October 24 investor webcast, which could offer further validation for personalized cancer treatment at scale. Moderna Adds Another 5% and Is Up 500% in 2026
Analyst Upgrades and Downgrades
Several research analysts have recently commented on MRNA shares. Jefferies Financial Group reiterated a “hold” rating on shares of Moderna in a report on Wednesday, August 19th. Citigroup raised their price target on Moderna from $41.00 to $60.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. William Blair started coverage on Moderna in a research note on Friday, August 28th. They issued an “outperform” rating on the stock. Brookline Capital Markets reissued a “buy” rating on shares of Moderna in a research note on Wednesday, August 19th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and set a $130.00 price target on shares of Moderna in a report on Wednesday, August 19th. Seven investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $76.72.
Moderna Trading Up 5.6%
The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The firm has a fifty day simple moving average of $101.83 and a two-hundred day simple moving average of $71.16. The firm has a market cap of $72.89 billion, a PE ratio of -22.85 and a beta of 1.10.
Moderna (NASDAQ:MRNA – Get Free Report) last posted its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The firm had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. During the same period in the previous year, the firm earned ($2.13) earnings per share. The business’s revenue was up 2.1% compared to the same quarter last year. Equities analysts forecast that Moderna, Inc. will post -6.09 EPS for the current year.
Insider Activity
In other Moderna news, CFO James M. Mock sold 34,836 shares of Moderna stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the sale, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. The trade was a 36.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the sale, the insider directly owned 74,129 shares in the company, valued at approximately $10,374,353.55. The trade was a 4.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 118,882 shares of company stock valued at $16,862,280. Corporate insiders own 10.80% of the company’s stock.
Institutional Investors Weigh In On Moderna
A number of hedge funds and other institutional investors have recently bought and sold shares of MRNA. Integrated Wealth Concepts LLC grew its stake in shares of Moderna by 17.0% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 7,653 shares of the company’s stock worth $536,000 after buying an additional 1,114 shares during the last quarter. NewEdge Advisors LLC raised its position in Moderna by 208.0% in the 2nd quarter. NewEdge Advisors LLC now owns 4,364 shares of the company’s stock worth $306,000 after buying an additional 2,947 shares during the last quarter. Baird Financial Group Inc. raised its holdings in shares of Moderna by 149.3% during the second quarter. Baird Financial Group Inc. now owns 11,918 shares of the company’s stock valued at $835,000 after purchasing an additional 7,137 shares during the last quarter. Waverly Advisors LLC bought a new position in shares of Moderna during the 2nd quarter valued at $243,000. Finally, Murphy Pohlad Asset Management LLC purchased a new position in Moderna in the second quarter worth about $268,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.
About Moderna
Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.
The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.
Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.
See Also
- Five stocks we like better than Moderna
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
